

Delbios Pharmaceuticals SL, new ICMAB-CSIC spin-off, secures Neotec 2025 funding

Delbios Pharmaceuticals SL, a new spin-off from the Institute of Materials Science of Barcelona (ICMAB-CSIC), has been awarded funding from the prestigious Neotec 2025 Programme (CDTI). The company, created by researchers from the Nanomol-Bio group, aims to bring innovative nanomedicines from advanced preclinical stages to early clinical development, translating cutting-edge research into real therapeutic solutions.



[Delbios Pharmaceuticals SL](#), a newly established spin-off from the Nanomol-Bio research group at the Institute of Materials Science of Barcelona (ICMAB-CSIC), has been awarded funding from the [Neotec 2025 Programme \(CDTI\)](#). This competitive programme supports technology-based start-ups that build on research-driven innovation and knowledge transfer.

Delbios focuses on advancing innovative nanomedicines from advanced preclinical stages to early clinical phases. The company's mission is to develop cutting-edge pharmaceutical products based on nanotechnology, contributing to the translation of academic research into real therapeutic solutions.

Founded in 2024 by [Nanomol-Bio](#) researchers Nora Ventosa, Elisabet González, and Judit Tomsen, together with [Nanomol Technologies SL](#) executives Santi Sala and Alba Córdoba, Delbios is based at the UAB Research Park and involves the participation of Nanomol Technologies SL and the CSIC. Following the creation of Nanomol Technologies SL in 2010, this represents a new spin-off arising from the Nanomol-Bio group.

Delbios' business model is based on acquiring patent licenses for products primarily originating from the Nanomol-Bio research group at ICMAB-CSIC, sometimes in collaboration with other academic institutions, hospitals, and companies. These nanomedicines are advanced to early clinical stages and subsequently licensed out to pharmaceutical companies (out-licensing).

[Continuing the Nano4Rare project](#)

Delbios has emerged within the framework of the European [Nano4Rare project](#) (ref. 101136772), funded by the European Innovation Council (EIC) under the EIC Transition programme. The project will complete the preclinical phase of *nanoGLA*, a liposomal-based nanopharmaceutical for the treatment of Fabry disease.

This development builds on previous Catalan, Spanish, and European projects and is protected by a process patent family and supported by multiple patent filings for platform and products, ensuring a strong Intellectual Property Rights Strategy. *nanoGLA* was designated as an Orphan Medicinal Product by the European Medicines Agency (EMA) in 2021.

[About the Neotec Programme](#)

The [Neotec Programme](#), promoted by the [Spanish Centre for the Technological Development and Innovation \(CDTI\)](#), aims to support the creation and consolidation of technology-based companies. It provides funding to start-ups that apply scientific and technological knowledge to develop new products, processes, or services.

With this achievement, Delbios Pharmaceuticals SL embarks on an exciting new stage filled with challenges and opportunities. At ICMAB-CSIC, we are confident that the company will become a benchmark in the field of nanomedicine and play a key role in transferring scientific knowledge into real health solutions. We wish Delbios every success in consolidating its growth, advancing innovation, and contributing to the well-being of society through its pioneering research.

More information

- [Ayudas Neotec 2025 | CDTI](#)
- [Resolución provisional Neotec 2025](#)
- [Delbios Pharmaceuticals](#)
- [Nano4Rare](#)
- [ICMAB - Nanostructured Molecular Materials for Biomedicine \(Nanomol-Bio\)](#)
- [Nanomol Technologies - Adding values to your molecules.](#)